Clinical trial
Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable…
NCT00182702 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00182702 |
|---|---|
| Title | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer |
| Official title | A Phase II Trial of BMS 247550 (Ixabepilone) in Advanced Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer |
| Intervention type | Drug, Other |
| Interventions | ixabepilone, laboratory biomarker analysis |
| Enrollment | 37 |
| Start date | Jul 1, 2005 |
| Primary completion | Sep 1, 2007 |
| First posted | Sep 16, 2005 |
| Last update posted | Mar 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: